Developing antibodies to disrupt cancer-cell metabolism in solid tumours
Pancreatic cancer is hard to detect early because the pancreas lies deep inside the body, beyond routine physical examination. People usually have no symptoms until the tumour has become very large or spread to other organs, making early detection a major challenge.
Analona Therapeutics develops antibody medicines targeting metabolic vulnerabilities in solid tumours, initially pancreatic cancer. It uses immunisation and tumour organoid screening to discover antibodies intended to treat these cancers.
What stands out about Analona Therapeutics
Reports dose-dependent tumour-cell killing by its top Target 1 antibodies in patient-derived pancreatic cancer organoids.
Joined BioInnovation Institute's Venture Lab, Cohort 7, in 2024, a programme supporting scientific and business development.
Co-founder and CSO Axel Behrens is a professor whose research identified cancer stem cells and therapeutic mechanisms in pancreatic tumours.
Co-founder Mikkel Wandahl Pedersen previously served as CSO of Symphogen, developing antibody-based drugs for cancer and other diseases.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.